Nastorazepide 是一种选择性的、口服有效的1,5-苯并二氮杂环衍生物胃泌素/胆囊收缩素2（CCK-2）受体拮抗剂，具有抗肿瘤的潜能。

Nastorazepide is a selective, orally available antagonist of gastrin/cholecystokinin 2 (CCK-2) receptor with potential antineoplastic activity.

Nastorazepide binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells[1].

Nastorazepide significantly inhibits the growth of subcutaneous xenografts of human pancreatic tumor cells in mice, and that Nastorazepide combined with gemcitabine prolonged survival in a pancreatic carcinoma orthotopic xenograft mice[1].

209219-38-5

C29H36N4O5

520.62

Z-360

DMSO:30 mg/mL (57.63 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years